If future CAR-NK studies can be designed to secrete a synthetic peptide that can inhibit CD271, this may be able to restore endogenous effector cell recruitment for concerted tumor cell elimination alongside CAR-NK cells. This evidence concerns the gene NGFR and neoplasm.